NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free AMLX Stock Alerts $1.88 -0.07 (-3.59%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$1.87▼$1.9950-Day Range$1.87▼$19.5752-Week Range$1.85▼$30.50Volume1.73 million shsAverage Volume2.82 million shsMarket Capitalization$127.43 millionP/E Ratio2.69Dividend YieldN/APrice Target$32.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Amylyx Pharmaceuticals alerts: Email Address Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside1,619.4% Upside$32.67 Price TargetShort InterestBearish12.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$193,098 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.01) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector281st out of 909 stocksPharmaceutical Preparations Industry122nd out of 423 stocks 4.1 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.63% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 18.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 0.8 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of -0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 34 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,098.00 in company stock.Percentage Held by Insiders11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to decrease in the coming year, from ($1.01) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is 2.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is 2.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.13.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesApril 17, 2024 | msn.comAmylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34April 15, 2024 | americanbankingnews.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Hold" from BrokeragesApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 12, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial ResultsApril 11, 2024 | markets.businessinsider.comHold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market ProspectsApril 10, 2024 | msn.comAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited DisorderApril 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 10, 2024 | businesswire.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 9, 2024 | prnewswire.comThe Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXApril 8, 2024 | markets.businessinsider.comOptimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare DiseasesApril 8, 2024 | stockhouse.com48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxApril 8, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)April 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024April 8, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue ImpactApril 8, 2024 | markets.businessinsider.comUnveiling 6 Analyst Insights On Amylyx PharmaApril 8, 2024 | prnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersApril 6, 2024 | finance.yahoo.comAnalysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS NumbersApril 5, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens BermanApril 5, 2024 | prnewswire.comAMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud LawsuitApril 5, 2024 | prnewswire.comAmylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXApril 4, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline DevelopmentsApril 4, 2024 | prnewswire.comAMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLXApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLXApril 4, 2024 | stockhouse.com5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmApril 4, 2024 | bizjournals.comAmylyx withdraws ALS drug after trial fail, slashes headcountApril 4, 2024 | bloomberg.comAmylyx to Pull ALS Drug From Market After Failed TrialSee More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees384Year FoundedN/APrice Target and Rating Average Stock Price Target$32.67 High Stock Price Target$48.00 Low Stock Price Target$8.00 Potential Upside/Downside+1,630.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$0.70 Trailing P/E Ratio2.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins12.94% Pretax Margin14.26% Return on Equity12.39% Return on Assets10.68% Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.20 Sales & Book Value Annual Sales$380.79 million Price / Sales0.34 Cash Flow$0.57 per share Price / Cash Flow3.31 Book Value$6.42 per share Price / Book0.29Miscellaneous Outstanding Shares67,780,000Free Float59,784,000Market Cap$127.97 million OptionableOptionable Beta-0.93 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Comp: $1MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Comp: $1MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Comp: $695.12kMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Comp: $794.83kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GMMr. Keith WhiteHead of Global Market AccessMore ExecutivesKey CompetitorsAnnovis BioNYSE:ANVSVistagen TherapeuticsNASDAQ:VTGNSagimet BiosciencesNASDAQ:SGMTSyros PharmaceuticalsNASDAQ:SYRSKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 15,247 shares on 4/18/2024Ownership: 0.023%Hennion & Walsh Asset Management Inc.Bought 27,937 shares on 4/17/2024Ownership: 0.167%Joshua B CohenSold 4,135 sharesTotal: $77,448.55 ($18.73/share)James M FratesSold 1,792 sharesTotal: $33,564.16 ($18.73/share)Gina MazzarielloSold 1,540 sharesTotal: $28,844.20 ($18.73/share)View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price target for 2024? 8 brokerages have issued 12-month price targets for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $8.00 to $48.00. On average, they anticipate the company's share price to reach $32.67 in the next year. This suggests a possible upside of 1,619.4% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2024? Amylyx Pharmaceuticals' stock was trading at $14.72 at the start of the year. Since then, AMLX stock has decreased by 87.1% and is now trading at $1.8999. View the best growth stocks for 2024 here. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted its quarterly earnings results on Thursday, February, 22nd. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.03. The business had revenue of $108.45 million for the quarter, compared to the consensus estimate of $106.40 million. Amylyx Pharmaceuticals had a net margin of 12.94% and a trailing twelve-month return on equity of 12.39%. During the same quarter last year, the company earned ($0.65) EPS. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an IPO on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.17%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.